Christine E Ryan

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Diffuse Large B Cell Lymphoma

Chronic Lymphocytic Leukemia

Top Venues

Future oncology (London, England)

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Christine E Ryan, Philippe Armand, Ann Steward LaCasce
Frontline Treatment of Mantle Cell Lymphoma. Blood (2024)
Christine E Ryan, Jonathon B Cohen
Is rituximab retro in mantle cell lymphoma? Blood 144 (3) (2024)
Christine E Ryan, Jonathon B Cohen
Is rituximab retro in mantle cell lymphoma? Blood 144 (3) (2024)
Christine E Ryan, Philippe Armand, Ann Steward LaCasce
Frontline Treatment of Mantle Cell Lymphoma. Blood (2024)
Christine E Ryan, Rebecca L Zon, Robert Redd, David C Fisher, Roni Shouval, Anita Kumar, Jennifer L Crombie, Hossein Sadrzadeh, Austin I Kim, Lakshmi Nayak, Ugonma N Chukwueke, Caron A Jacobson, Matthew J Frigault, M Lia Palomba, Philippe Armand, Zachary D Epstein-Peterson, Reid W Merryman
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British journal of haematology (2023)
Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett, Mary C Collins, Stacey M Fernandes, Yue Ren, Yinglu Zhou, Mikaela M McDonough, Heather A Walker, Monica R McEwan, Jeremy S Abramson, Eric D Jacobsen, Ann S LaCasce, David C Fisher, Jennifer R Brown, Matthew S Davids
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia (2023)
Christine E Ryan, Matthew S Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P Sharman, Anthony R Mato, Lindsey Elizabeth Roeker
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future oncology (London, England) (2022)